Cerebrolysin vs PE-22-28
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: FPE 1070
A mixture of low-molecular-weight neuropeptides derived from pig brain. Approved in many countries for stroke, traumatic brain injury, and dementia.
Also: PE22-28, Spadin Analog
A synthetic heptapeptide (7 amino acids) derived from Spadin, a naturally occurring antidepressant peptide. PE-22-28 is a shorter, more stable analog that retains the antidepressant and anxiolytic properties of Spadin. Works by blocking TREK-1 potassium channels in the brain.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- Cerebrolysin has stronger research evidence (Human Trials) compared to PE-22-28 (Animal Studies).
Detailed Comparison
| Attribute | Cerebrolysin | PE-22-28 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Cerebrolysin contains neurotrophic factors that mimic BDNF, NGF, and CNTF activity. It enhances neuroplasticity, protects neurons from excitotoxicity, promotes neurogenesis, and improves synaptic function. | PE-22-28 selectively blocks TREK-1 (TWIK-related potassium channel 1), a two-pore domain potassium channel highly expressed in the brain. TREK-1 inhibition increases neuronal excitability and enhances serotonergic and noradrenergic neurotransmission. This mechanism is distinct from traditional SSRIs and produces rapid-onset antidepressant effects in preclinical studies. |
| Common Dosing | 5-10 ml IV/IM daily for 10-20 days Daily during treatment cycles | 100-300 mcg intranasal or subcutaneous Once daily |
| Administration | Intravenous or intramuscular injection | Intranasal or subcutaneous injection |
| Typical Duration | 10-20 day cycles | Research protocols vary, often 2-4 weeks |
| Best Time to Take | Morning | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Approved in over 40 countries for neurological conditions. Studies show benefits in stroke recovery, Alzheimer's disease, and TBI. Large clinical trials demonstrate improved cognitive function and activities of daily living. | Animal studies demonstrate significant antidepressant and anxiolytic effects within days of administration (faster than traditional SSRIs which take weeks). PE-22-28 shows improved stability compared to full Spadin while maintaining efficacy. Research indicates potential for treatment-resistant depression. No human clinical trials conducted yet. |
Frequently Asked Questions: Cerebrolysin vs PE-22-28
What is the difference between Cerebrolysin and PE-22-28?
Cerebrolysin is a cognitive peptide that a mixture of low-molecular-weight neuropeptides derived from pig brain. approved in many countries for stroke, traumatic brain injury, and dementia. PE-22-28 is a cognitive peptide that a synthetic heptapeptide (7 amino acids) derived from spadin, a naturally occurring antidepressant peptide. pe-22-28 is a shorter, more stable analog that retains the antidepressant and anxiolytic properties of spadin. works by blocking trek-1 potassium channels in the brain. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Cerebrolysin or PE-22-28?
Neither is universally "better" - the choice depends on your specific goals. Cerebrolysin is typically used for cognitive purposes, while PE-22-28 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Cerebrolysin and PE-22-28 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Cerebrolysin and PE-22-28 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.